Skip to main content
NeopharmCO.,LTD. logo

NeopharmCO.,LTD. — Investor Relations & Filings

Ticker · 092730 ISIN · KR7092730001 KO Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2020-02-17 Director's Dealing
Country KR South Korea
Listing KO 092730

About NeopharmCO.,LTD.

https://neopharm.co.kr

Neopharm is a science-based company specializing in the development, manufacturing, and sale of dermatological skincare and cosmetic products. A pioneer in skin barrier research, the company focuses on restoring skin homeostasis. Its core innovation is the proprietary Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin to repair and strengthen its protective functions. The company's primary product lines, including the flagship brand Atopalm, are specifically formulated for sensitive, dry, and compromised skin. These non-steroid solutions are grounded in dermatological science to address various skin concerns.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a mandatory disclosure of personal share transactions by company directors or executives, which corresponds to the 'Director's Dealing' category.
2020-02-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership (specifically '장내매수' or on-market purchase), and the relationship between the reporter and the issuer (Neopharm). This falls under the category of Major Shareholding Notification.
2020-02-17 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a formal announcement of preliminary financial results (영업(잠정)실적) for Neopharm. It provides key financial highlights such as revenue, operating profit, and net income for the quarter and cumulative year-to-date. As it is an initial announcement of quarterly financial results containing key highlights, it fits the definition of an Earnings Release (ER). Q4 2019
2020-02-07 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Neopharm regarding a decision on cash dividends. It specifies the dividend amount per share (750 KRW), the dividend yield, the total dividend amount, and the record date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2020-02-07 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the changes in share ownership by KB Asset Management in the company Neopharm. This falls under the 'Major Shareholding Notification' category as it tracks changes in significant ownership levels.
2020-02-05 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal regulatory notice of a corporate action. Given the nature of the announcement, it falls under the general regulatory filing category.
2019-12-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.